Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-09-02
2011-12-13
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S252050, C544S182000, C544S238000, C544S239000
Reexamination Certificate
active
08076334
ABSTRACT:
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
REFERENCES:
patent: 4188388 (1980-02-01), Thuillier, born Nachmias et al.
patent: 5284971 (1994-02-01), Walker et al.
patent: 188351 (1986-07-01), None
patent: 728482 (1996-08-01), None
patent: WO 9702023 (1997-01-01), None
patent: WO 9857919 (1998-12-01), None
patent: WO 9900353 (1999-01-01), None
patent: WO 2005051298 (2005-06-01), None
patent: WO 2007/009913 (2007-01-01), None
Paul M. Yen Physiological Review, vol. 81(3): pp. 1097-1126 (2001).
M.A. Lazar Endocrine Reviews, vol. 14: pp. 348-399 (1993).
Abel et. al. J. Clin. Invest., vol. 104: pp. 291-300 (1999).
B. Gloss et. al. Endocrinology, vol. 142: pp. 544-550 (2001).
C. Johansson et. al. Am. J. Physiol., vol. 275: pp. R640-R646 (1998).
Paul Webb Expert Opin. Investig. Drugs, vol. 13(5): pp. 489-500 (2004).
Eugene Morkin et. al. Journal of Molecular and Cellular Cardiology, vol. 37: pp. 1137-1146 (2004).
J.J. Abrams et. al. J. Lipid Res., vol. 22: pp. 323-338 (1981).
M. Aviram et. al. Clin. Biochem., vol. 15: pp. 62-66 (1982).
Gene C. Ness et. al. Biochemical Pharmacology, vol. 56: pp. 121-129 (1998).
G.J. Grover et. al. Endocrinology, vol. 145: pp. 1656-1661 (2004).
G.J. Grover et. al. Proc. Natl. Acad. Sci. USA, vol. 100: pp. 10067-10072 (2003).
De Bruin et. al. J. Clin. Endo. Metab., vol. 76: pp. 121-126 (1993).
A.H. Underwood et al. Nature,vol. 324 pp. 425-429 (1986).
Thomas S. Scalan Current Opinion in Drug Discovery & Development, vol. 4 (5): pp. 614-622 (2001).
Malm Johan Current Pharmaceutical Design, vol. 10(28): pp. 3525-3532 (2004).
Expert Opin. Ther. Patents, vol. 14: pp. 1169-1183 (2004).
Teruomi et. al. Agricultural and Biological Chemistry, vol. 38(6): pp. 1169-1176 (1974).
P.D. Leeson et. al. J. Med. Chem.vol. 32: pp. 320-326 (1989).
Valentino, Stella, Advanced Drug Delivery Reviews XP002080432, (1989).
Fleisher D, Improved oral drug delivery XP002389735, (1996).
Simplicio, Ana Molecules, XP 002503564, (1996).
Haynes Nancy-Ellen
Scott Nathan
Tilley Jefferson Wright
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
Ward Paul V.
LandOfFree
Prodrugs of thyroid hormone analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs of thyroid hormone analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of thyroid hormone analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4267033